Pulmonary Tuberculosis and Granulomatous Lung Diseases
Connect the organism, host response, lung pathology, clinical clues, treatment and prevention into one rapid-revision pathway.
1. THE TOPIC IN ONE CONNECTED FLOW
Pulmonary tuberculosis begins when Mycobacterium tuberculosis reaches the alveoli and survives within macrophages. The host then develops a cell-mediated immune response that forms granulomas, producing either containment or progressive tissue injury. The same disease process explains the clinical presentation, diagnostic approach, multidrug treatment and public-health need to interrupt transmission. :contentReference[oaicite:0]{index=0}
TB produces predominantly caseating granulomas, while sarcoidosis classically produces well-formed non-necrotizing granulomas. Hypersensitivity pneumonitis links repeated inhaled antigen exposure to bronchiolocentric lymphocytic inflammation and poorly formed granulomas, whereas pulmonary eosinophilia reflects eosinophil-rich inflammation from allergic, drug-related, parasitic or related causes.
2. KEY CLINICAL CONNECTIONS
Caseating granulomatous inflammation → tissue destruction and cavity formation → persistent cough, weight loss and hemoptysis → upper-zone abnormalities plus microbiological confirmation from respiratory specimens.
Well-formed non-necrotizing granulomas + bilateral hilar lymphadenopathy → consider sarcoidosis, but exclude infection.
Repeated inhalational exposure + centrilobular nodules/air trapping → immune-mediated hypersensitivity pneumonitis.
Isoniazid → reduced mycolic-acid synthesis → strong activity against multiplying bacilli → watch for neuropathy and hepatotoxicity.
Rifampicin → inhibition of bacterial RNA synthesis → bactericidal and sterilizing effect → major enzyme induction can alter other medicines.
3. AIM HIGH-YIELD INTEGRATION REVIEW
A granuloma is a pattern of chronic inflammation, not a diagnosis by itself. Morphology must be linked with microbiology, exposure history, imaging and clinical context.